Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-02-13

Clinical Trial Update: Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of LX9211 in postherpetic neuralgia has completed, with results posted by the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LX9211

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Postherpetic Neuralgia | Phase 2 | Status: COMPLETED | Results posted: 2026-02-13